Haleon (NYSE:HLN) Sees Large Volume Increase – Should You Buy?

Haleon PLC Sponsored ADR (NYSE:HLN) saw unusually-high trading volume on Friday . Approximately 7,510,183 shares changed hands during mid-day trading, a decline of 20% from the previous session’s volume of 9,395,404 shares.The stock last traded at $9.2550 and had previously closed at $9.36.

Analyst Ratings Changes

Several brokerages have recently commented on HLN. Zacks Research raised Haleon from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Haleon in a report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Haleon Stock Performance

The company has a market capitalization of $40.62 billion, a PE ratio of 23.71, a price-to-earnings-growth ratio of 2.05 and a beta of 0.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. The stock’s fifty day simple moving average is $9.82 and its 200-day simple moving average is $9.64.

Haleon Cuts Dividend

The company also recently disclosed a dividend, which was paid on Thursday, September 17th. Stockholders of record on Friday, August 14th were given a $0.0642 dividend. This represents a dividend yield of 132.0%. The ex-dividend date of this dividend was Friday, August 14th. Haleon’s payout ratio is currently 30.77%.

Institutional Trading of Haleon

A number of hedge funds have recently bought and sold shares of the company. WINTON GROUP Ltd purchased a new stake in Haleon in the 2nd quarter worth approximately $494,000. Engineers Gate Manager LP purchased a new position in shares of Haleon during the 2nd quarter worth $1,869,000. NorthRock Partners LLC lifted its stake in shares of Haleon by 31.5% during the 2nd quarter. NorthRock Partners LLC now owns 52,244 shares of the company’s stock worth $487,000 after purchasing an additional 12,500 shares during the period. Integrated Wealth Concepts LLC boosted its holdings in shares of Haleon by 48.9% during the second quarter. Integrated Wealth Concepts LLC now owns 17,170 shares of the company’s stock worth $160,000 after purchasing an additional 5,636 shares during the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in shares of Haleon by 19.4% during the second quarter. NewEdge Advisors LLC now owns 133,508 shares of the company’s stock worth $1,246,000 after purchasing an additional 21,693 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE: HLN) is a global consumer healthcare company that develops, manufactures and markets products for everyday health and wellness needs. Its portfolio spans oral health, pain relief, respiratory health, vitamins and supplements, digestive health, and therapeutic skin care.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Voltaren, Panadol, Advil, Centrum, Emergen-C, Theraflu, Otrivin, Calpol, ChapStick and Excedrin. The company sells its products through pharmacies, supermarkets, mass retailers, e-commerce platforms and other healthcare channels.

Haleon was formed through the demerger of GSK’s consumer healthcare business and became an independent company in 2022.